• 1
    Horsburgh CR. Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. N Engl J Med 1991; 324: 13321338.
  • 2
    Gill J, Moyle G, Nelson M. Discontinuation of Mycobacterium avium complex prophylaxis in patients with a rise in CD4 cell count following highly active antiretroviral therapy. AIDS 1998; 12: 680.
  • 3
    USPHS/ IDSA. Guidelines for the prevention of opportunistic infections in persons infected with Human Immunodeficiency virus. Clin Infect Dis 2000; 30: S29S65.
  • 4
    Dworkin M, Hanson D, Jones J, Kaplan J. Adult/Adolescent Spectrum of HIV Disease Project (ASD). The risk for Pneumocystis carinii pneumonia (PCP) and disseminated non-tuberculous mycobacteriosis (dMb) after an antiretroviral therapy (ART) associated increase in CD4+ T-lymphocyte count [abstract 692]. In Program and Abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago) 1999: 198.
  • 5
    Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853860.
  • 6
    Strolin Benedetti M, Dostert P. Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies. Environ Health Perspect 1994; 102(Suppl 9): 101105.
  • 7
    Iatsimirskaia E, Tulebaev S, Storozhuk E, et al. Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents. Clin Pharmacol Ther 1997; 61: 554562.
  • 8
    Schuetz EG, Schinkel AH, Relling MV, Schuetz JD. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 1996; 93: 40014005.
  • 9
    Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147153.
  • 10
    Fromm MF. P-glycoprotein: a defense mechanism limiting oral bioavailability and CNS accumulation of drugs. Int J Clin Pharmacol Ther 2000; 38: 6974.
  • 11
    Sahai J. Interactions with antiretroviral drugs. AIDS 1996; 10: S21S25.
  • 12
    Ingrosso A, De Cian W, Narang PK. Update on results from drug-interaction studies with rifabutin [abstract 463]. In Program and Abstracts of the 6th European Conference on Clinical Aspects and Treatment of HIV-Infection (Hamburg) 1997: 76.
  • 13
    Fournier S, Deplus S, Janier M, Poinsignon Y, Decazes JM, Modai J. Anterior uveitis in HIV-infected patients. Three cases in patients treated with an antiprotease. Presse Med 1998; 27: 844848.
  • 14
    Gieschke R, Fotteler B, Buss N, Steimer JL. Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients. Clin Pharmacokin 1999; 37: 7586.
  • 15
    Veldkamp AI, Hoetelmans RMW, Beijnen JH, Mulder JW, Meenhorst PL. Ritonavir enables combined therapy with rifampin and saquinavir. Clin Infect Dis 1999; 29: 1586.
  • 16
    Gallicano K, Khaliq Y, Carignan G, Tseng A, Walmsley S, Cameron DW. A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus. Clin Pharmacol Ther 2001; 70: 149158.
  • 17
    Hoetelmans RMW, Van Heeswijk RPG, Meenhorst PL, Mulder FW, Scheele WA, Beijnen FH. Plasma concentrations of saquinavir (SQV) determine HIV-1 RNA response over a 48-week period [abstract 42261]. In Program and Abstracts of the 12th World AIDS Conference (Geneva) 1998: 825.
  • 18
    Wiltshire HR, Wiltshire BG, Clarke AF, Worth E, Prior KJ, Tjia JF. Chromatographic and immunochemical approaches to the analysis of the HIV protease inhibitor saquinavir in plasma. Anal Biochem 2000; 281: 105114.